Atlas Trials

Stage IVC Salivary Gland Cancer

17 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Stage IVC Salivary Gland Cancer

RecordFirmDate
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer (NCT02245100)Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University2014-07-22
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT02123511)Mayo Clinic2014-04-01
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01816984)University of Chicago2013-05-01
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675)Sanjiv Sam Gambhir2013-03-04
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (NCT01613768)University of Washington2012-05-08
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137)Stanford University2012-05-01
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (NCT00939627)National Cancer Institute (NCI)2009-07-01
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (NCT01637194)Fox Chase Cancer Center2008-11-01
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. (NCT01469429)Ohio State University Comprehensive Cancer Center2007-09-04
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00507767)National Cancer Institute (NCI)2007-07-01
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer (NCT00126607)National Cancer Institute (NCI)2005-07-01
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00095628)National Cancer Institute (NCI)2005-01-01
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00096512)National Cancer Institute (NCI)2004-10-01
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497)National Cancer Institute (NCI)2003-08-01
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck (NCT00033618)National Cancer Institute (NCI)2002-11-01

Track Stage IVC Salivary Gland Cancer automatically

Every clearance here is in the API, with alerts when new ones post.